Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 10/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GHSR | Q92847 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 3/20 | 0.46 |
| ▸ | F11 | P03951 | 4/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3609812 | 0.88 | XIAP (0.55) | XIAPGHSRACE | |
| SCHEMBL3607633 | 0.85 | XIAP (0.53) | XIAPKMT2AACEF11 | |
| SCHEMBL3612449 | 0.83 | XIAP (0.50) | XIAPKMT2AACEF11 | |
| SCHEMBL3604048 | 0.80 | XIAP (0.49) | XIAPACE | |
| SCHEMBL3610720 | 0.77 | XIAP (0.46) | XIAPLMNAKMT2AACE | |
| SCHEMBL3612823 | 0.77 | XIAP (0.44) | XIAPGHSRACEF11 | |
| SCHEMBL8800082 | 0.76 | KMT2A (0.55) | LMNAKMT2A | |
| SCHEMBL16303966 | 0.75 | ACE (0.50) | KMT2AACEF11 | |
| SCHEMBL3608978 | 0.74 | XIAP (0.44) | XIAPKMT2A | |
| SCHEMBL3612314 | 0.73 | XIAP (0.43) | XIAPGHSRACEF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-1857444-A1 | TETRAHYDROISOQUINOLINE COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | ACAT1, ACAT2, LCAT | XIAP 934/4885LMNA 4557/4885KMT2A 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.